The current understanding and potential therapeutic options to combat COVID-19
Copyright © 2020. Published by Elsevier Inc..
The ongoing wreaking global outbreak of the novel human beta coronavirus (CoV) pathogen was presumed to be from a seafood wholesale market in Wuhan, China, belongs to the Coronaviridae family in the Nidovirales order. The virus is highly contagious with potential human-human transmission which was named as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread across six continents and emerged as a global pandemic in short span with alarming levels of spread and severity. This virus associated symptoms and infectious respiratory illness is designated as coronavirus disease 19 (COVID-19). The SARS-CoV-2 possesses enveloped club-like spike protein projections with positive-sense large RNA genome and has a unique replication strategy. This virus was believed to have zoonotic origin with genetical identity to bat and pangolin CoV. In the current review, we introduce a general overview about the human CoVs and the associated diseases, the origin, structure, replication and key clinical events that occur in the COVID-19 pathogenicity. Furthermore, we focused on possible therapeutic options such as repurposing drugs including antimalarials, antivirals, antiparasitic drugs, and anti-HIV drugs, as well as monoclonal antibodies, vaccines as potential treatment options. Also we have summarized the latest research progress on the usage of stem cell therapy, human convalescent serum, interferon's, in the treatment of COVID-19.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:254 |
---|---|
Enthalten in: |
Life sciences - 254(2020) vom: 01. Aug., Seite 117765 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pooladanda, Venkatesh [VerfasserIn] |
---|
Links: |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
Date Completed 22.06.2020 Date Revised 26.09.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.lfs.2020.117765 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM310200644 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM310200644 | ||
003 | DE-627 | ||
005 | 20231225135554.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.lfs.2020.117765 |2 doi | |
028 | 5 | 2 | |a pubmed24n1033.xml |
035 | |a (DE-627)NLM310200644 | ||
035 | |a (NLM)32437797 | ||
035 | |a (PII)S0024-3205(20)30513-0 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pooladanda, Venkatesh |e verfasserin |4 aut | |
245 | 1 | 4 | |a The current understanding and potential therapeutic options to combat COVID-19 |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.06.2020 | ||
500 | |a Date Revised 26.09.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020. Published by Elsevier Inc. | ||
520 | |a The ongoing wreaking global outbreak of the novel human beta coronavirus (CoV) pathogen was presumed to be from a seafood wholesale market in Wuhan, China, belongs to the Coronaviridae family in the Nidovirales order. The virus is highly contagious with potential human-human transmission which was named as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread across six continents and emerged as a global pandemic in short span with alarming levels of spread and severity. This virus associated symptoms and infectious respiratory illness is designated as coronavirus disease 19 (COVID-19). The SARS-CoV-2 possesses enveloped club-like spike protein projections with positive-sense large RNA genome and has a unique replication strategy. This virus was believed to have zoonotic origin with genetical identity to bat and pangolin CoV. In the current review, we introduce a general overview about the human CoVs and the associated diseases, the origin, structure, replication and key clinical events that occur in the COVID-19 pathogenicity. Furthermore, we focused on possible therapeutic options such as repurposing drugs including antimalarials, antivirals, antiparasitic drugs, and anti-HIV drugs, as well as monoclonal antibodies, vaccines as potential treatment options. Also we have summarized the latest research progress on the usage of stem cell therapy, human convalescent serum, interferon's, in the treatment of COVID-19 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Repurposing drugs | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a Spike proteins | |
650 | 4 | |a Zoonotic origin | |
700 | 1 | |a Thatikonda, Sowjanya |e verfasserin |4 aut | |
700 | 1 | |a Godugu, Chandraiah |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Life sciences |d 1965 |g 254(2020) vom: 01. Aug., Seite 117765 |w (DE-627)NLM000007579 |x 1879-0631 |7 nnns |
773 | 1 | 8 | |g volume:254 |g year:2020 |g day:01 |g month:08 |g pages:117765 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lfs.2020.117765 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 254 |j 2020 |b 01 |c 08 |h 117765 |